I
Immetas
Discovers and develops novel therapeutics that modulate the innate immune system to treat age-related cancers and inflammatory diseases
About Immetas
Immetas is a biotechnology company focused on discovering and developing novel therapeutics that modulate the innate immune system to treat age-related cancers and inflammatory diseases. The company operates in the biopharmaceutical market, targeting chronic inflammation as a fundamental process governing aging and related diseases. Immetas serves patients suffering from chronic inflammatory conditions and age-related cancers, aiming to provide innovative treatments that address the underlying causes of these diseases.
The business model of Immetas involves extensive research and development (R&D) to identify and create new therapeutic compounds. The company collaborates with academic institutions, leveraging cutting-edge scientific research to drive its drug discovery efforts. Revenue is generated through the development and commercialization of these therapeutics, including potential partnerships with larger pharmaceutical companies for distribution and marketing.
Immetas makes money primarily through licensing agreements, milestone payments, and royalties from the sale of its developed drugs. The company also seeks funding from investors to support its R&D activities and advance its therapeutic candidates through clinical trials.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2018
- Headquarters
- East Hanover, United States
- Open positions
- None listed
- Dealroom signal
- 22.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
- Links
- Website
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Sep 2020 | $11M | $44M | Morningside | — |
Growth signals
Latest recorded traffic for Immetas is 1.7K monthly website visits, up 146.4% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Immetas on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Immetas’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.